Pfizer Inc. (PFE) — closed signal from February 23, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on May 24, 2026.
Predicted vs. what happened
What happened
Hit or exceeded the predicted growth inside the window.
The thesis — published February 23, 2026
Pfizer is the kind of stock people buy for steady income rather than quick gains. Its dividend keeps interest from investors who want cash payouts, and merger and acquisition news in healthcare keeps big drug companies like Pfizer in focus. The price has been weak but appears to be forming a low; any upside is likely to be slow, so buy close to support and only add if the stock shows follow-through.
Primary drivers
- Dividend income draws demand when markets shift toward safety
- M&A chatter keeps large pharma in investor conversations
- Price forming a base can reward patient, disciplined buying
- Expected gains are slow, so avoid chasing rallies
How it played out
PFE: target stayed just out of reach
Lyra published PFE at 26.76 on 2026-02-23, with expected growth of 8% and a 28.9 target. The thesis was cautious. It pointed to dividend income, healthcare merger and acquisition chatter, a possible base after weakness, and slow upside that required patience rather than chasing rallies.
Inside the window, the stock peaked at 28.75 on 2026-04-02, for a 7.4% gain. That stayed below the target. It never got there. By 2026-05-24, PFE ended at 25.9, below the publication price. The thesis partly played out on the rise, but missed its target and did not hold the gain.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.